Recognition sites of monoclonal antibodies A4 and A24 in the α-latrotoxin molecule

Lazareva, V. D.; Bocharova, N. E.; Volynski, Kirill E.; Volkova, T. D.; Grishin, Eugene V.

doi:10.1007/bf02759166

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies are widely used in many diagnostic and therapeutic applications, and having a monoclonal antibody targeting a-LTX could be of utility in both the research setting as an affinity agent, when latrotoxins are employed for experimentation, and in the clinical setting when widow spider bites are suspected. Murine monoclonal antibodies against a-LTX have been produced and successfully applied in studies of the mode of action of the toxin (24)(25)(26)(27); they are nowadays used for its affinity purification. Phage display technology has previously been used to discover recombinant human monoclonal antibodies against animal toxins.…”

Section: Introductionmentioning

confidence: 99%

Discovery of a Recombinant Human Monoclonal Immunoglobulin G Antibody Against α-Latrotoxin From the Mediterranean Black Widow Spider (Latrodectus tredecimguttatus)

et al. 2020

View full text Add to dashboard Cite

Widow spiders are among the few spider species worldwide that can cause serious envenoming in humans. The clinical syndrome resulting from Latrodectus spp. envenoming is called latrodectism and characterized by pain (local or regional) associated with diaphoresis and nonspecific systemic effects. The syndrome is caused by α-latrotoxin, a ~130 kDa neurotoxin that induces massive neurotransmitter release. Due to this function, α-latrotoxin has played a fundamental role as a tool in the study of neuroexocytosis. Nevertheless, some questions concerning its mode of action remain unresolved today. The diagnosis of latrodectism is purely clinical, combined with the patient’s history of spider bite, as no analytical assays exist to detect widow spider venom. By utilizing antibody phage display technology, we here report the discovery of the first recombinant human monoclonal immunoglobulin G antibody (TPL0020_02_G9) that binds α-latrotoxin from the Mediterranean black widow spider ( Latrodectus tredecimguttatus ) and show neutralization efficacy ex vivo . Such antibody can be used as an affinity reagent for research and diagnostic purposes, providing researchers with a novel tool for more sophisticated experimentation and analysis. Moreover, it may also find therapeutic application in future.

show abstract

Section: Introductionmentioning

confidence: 99%